Filter News
Area of Research
- (-) Neutron Science (1)
- (-) Nuclear Science and Technology (2)
- Advanced Manufacturing (1)
- Biology and Environment (1)
- Clean Energy (9)
- Computer Science (1)
- Energy Frontier Research Centers (1)
- Isotope Development and Production (1)
- Materials (18)
- National Security (1)
- Quantum information Science (1)
- Supercomputing (5)
News Type
Media Contacts
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
With the production of 50 grams of plutonium-238, researchers at the Department of Energy’s Oak Ridge National Laboratory have restored a U.S. capability dormant for nearly 30 years and set the course to provide power for NASA and other missions.